- Home
- MXE vs DTIL Comparison
MXE vs DTIL Comparison
Compare MXE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXE
- DTIL
- Stock Information
- Founded
- MXE 1990
- DTIL 2006
- Country
- MXE United States
- DTIL United States
- Employees
- MXE N/A
- DTIL N/A
- Industry
- MXE Finance Companies
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- MXE Finance
- DTIL Health Care
- Exchange
- MXE Nasdaq
- DTIL Nasdaq
- Market Cap
- MXE 51.3M
- DTIL 55.3M
- IPO Year
- MXE N/A
- DTIL 2019
- Fundamental
- Price
- MXE $11.66
- DTIL $4.61
- Analyst Decision
- MXE
- DTIL Strong Buy
- Analyst Count
- MXE 0
- DTIL 2
- Target Price
- MXE N/A
- DTIL $47.00
- AVG Volume (30 Days)
- MXE 5.8K
- DTIL 78.0K
- Earning Date
- MXE 01-01-0001
- DTIL 11-03-2025
- Dividend Yield
- MXE 2.66%
- DTIL N/A
- EPS Growth
- MXE N/A
- DTIL N/A
- EPS
- MXE N/A
- DTIL N/A
- Revenue
- MXE N/A
- DTIL $1,261,000.00
- Revenue This Year
- MXE N/A
- DTIL N/A
- Revenue Next Year
- MXE N/A
- DTIL $135.19
- P/E Ratio
- MXE N/A
- DTIL N/A
- Revenue Growth
- MXE N/A
- DTIL N/A
- 52 Week Low
- MXE $8.40
- DTIL $3.61
- 52 Week High
- MXE $11.51
- DTIL $10.71
- Technical
- Relative Strength Index (RSI)
- MXE 70.97
- DTIL 40.75
- Support Level
- MXE $10.95
- DTIL $4.86
- Resistance Level
- MXE $11.69
- DTIL $5.17
- Average True Range (ATR)
- MXE 0.26
- DTIL 0.24
- MACD
- MXE 0.03
- DTIL -0.03
- Stochastic Oscillator
- MXE 96.28
- DTIL 16.18
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.